ServiziMenu principaleHome
You are here: Home > Educational Opportunities > Past events > 2012 > BCY1 - Breast Cancer in Young Women Conference
Share on Share on Facebook Twitter Share on Linkedin Share on WhatsApp Share on Instagram Share by email Print this page

BCY1 - Breast Cancer in Young Women Conference

15 ESCO credits

08.11.2012  -  10.11.2012

Dublin, Ireland


Breast cancer


F. Cardoso, PT - B. Kaufman, IL - A. Partridge, US
Host-Chair: J. Geraghty, IE
Scientific Committee: S. Aebi, CH - H.A. Azim Jr, BE - G. Freilich, UK - M.C. King, US - F.A. Peccatori, IT

Breast cancer in young women is a devastating and complex disease. Breast cancer in women under 40 strikes when these women are at the peak of their reproductive years, family life and careers and still have many years ahead of them to suffer the long-term effects of treatment or the consequences of recurrent disease. The etiology of breast cancer in this population is poorly understood and most clinical trials focus on women who are over the age of 40, thus little evidence-based data is available about the optimal management of these patients. Further research is much needed in this field. This conference is an opportunity for the latest updates on this field and a platform for generating future research concepts and collaborations. It will cover epidemiology, molecular biology, genetics, pathology, surgery, radiotherapy, systemic therapy, sexuality and fertility preservation in young women with breast cancer.
We hope that you will join us and contribute to further develop the understanding and treatment of this disease.

On behalf of the Chairs and Scientific Committee Members,

B. Kaufman

• Hereditary breast cancer
• Diagnostic tools in young women
• Local therapy
• Systemic therapy
• Pregnancy and breast cancer
• Fertility preservation
• Psychosocial aspects
• Management of side effects
• Case discussions

• Medical oncologists
• Surgeons
• Gynaecologists
• Radiation oncologists
• Onco-geneticists
• Phatologists
• Nurses
• Patient advocates

General information

European School of Oncology (ESO)
Via del Bollo, 4
20123 Milan - Italy
Francesca Marangoni -
fmarangoni@eso.net Tel: +39 02 85464525
Roberta Ventura -
rventura@eso.net Tel: +39 02 85464532

O’Reilly Hall
University College Dublin
Belfield, Dublin 4
Map available here

O'Reilly Hall
, the venue for BCY1 2012 is located in Belfield, the main University College Dublin campus, 4km south of Dublin city centre. UCD is directly accessible by bus, private car and taxi. O’Reilly Hall is located centrally on campus beside the lake. The most convenient vehicular and pedestrian access to this building is through the main gate in UCD via the N11. Enter through the main gate (N11) and turn right. Follow the road until you can see a large car park to your left, O’ Reilly Hall is overlooking this car park.  Please see the UCD map for exact location of O'Reilly Hall (ref C7).
Dublin International Airport Transport Links to UCD
Dublin is served by Dublin International Airport, which is located north of Dublin City Centre. Aircoach operates a service from Dublin Airport to Leopardstown / Sandyford / Stillorgan which passes UCD. Further details available at www.aircoach.ie/
Dublin Bus Links to UCD
Dublin Bus numbers 2, 3, 11, 17, 39A, 46A, 84 and 145 all provide services to the Belfield campus. The 39A terminates within the Belfield campus, and can be boarded from in the City Centre from College Street. The numbers 2, 3, 11 and 46A can be boarded at O'Connell Street. Several additional Xpresso services operate directly to campus during morning and evening peak. For timetable information please visit www.dublinbus.ie/ and search for University College Dublin.
Irish Rail Links to UCD
Dublin is served by two main railway stations: Connolly Station and Heuston Stations. It is a short walk from Connolly Station to O'Connell Street, where the Dublin Bus numbers 2, 11 and 46A can be boarded for UCD. The route 145 provides a direct route from Heuston Station to Belfield via the city centre. For further information please visit www.irishrail.ie
Regional Bus Links to UCD
Bus Éireann provides a nationwide bus service, with most major areas having a regular link to Dublin. The majority of Dublin services terminate in Busáras (Central Bus Station, Dublin) from where it is a short walk to O'Connell Street for connecting buses to UCD. Several Bus Éireann services from the Greater Dublin area directly serve UCD, Belfield Campus during morning peak. For further information please visit www.buseireann.ie

Taxis to UCD
There are usually an adequate number of taxis in operation in the city centre at any given time. It is possible to hail a taxi from the street, but convenient taxi ranks are located on O'Connell Street, Middle Abbey Street, Dame Street and St Stephens Green.

The official language will be English. No translation will be provided.

The badge is the only offical evidence of registration and should be worn at all times during the conference. Loss of badge means loss of registration.

The organizers bear no responsibility for untoward events in relation to the participation in the Conference. Participants are advised to take out their own personal and travel insurance coverage.

An abstract book will be published as supplement to The Breast and will contain abstracts of the invited lecturers and those submitted by the participants that have been accepted for oral or poster presentation or for publication only. The three best abstracts will be selected and proposed for oral presentation (Free registration will be granted to the first author of the three selected abstracts). Oral presentations will be scheduled on 8 November and poster session will be scheduled on 9 November. 
Thanks to the generous support of SFI (Science Foundation Ireland), the three best abstracts will also receive a prize of 350€ each. The awards will be presented at the conference. Further details will be provided directly to the authors.

Participants will be issued a certificate of attendance.
Application for CME recognition has been submitted to ESMO for ESMO-MORA accreditation, to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). The event was granted 12 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).
EACCME credits are recognized by the American Medical Association towards the Physician’s Recognition Award (PRA). EACCME certificate will be recognised by the Irish Postgraduate Training Bodies and Irish participants will be entitled to record these credits for purposes of Continuing Professional Development (CDP).
The programme was furthermore awarded with 14 cat. 1 ESMO-MORA points.

ESO is grateful to The Breast Cancer Research Foundation, Susan G. Komen for the Cure! And the Irish Cancer Foundation for having provided travel grants
to support the participation of:

Ekaterine Abashidze (Georgia), Omar Abdelrhman (Egypt), Oluwagbemiga AbdulRazzak Lawal (Nigeria), Akshay Anand Agarwal (India), Farah Arshad (India), Olexiy Aseyev (Ukraine), Antoinette Attard (Malta), Bettina Ballardini (Italy), Kumar Manoj Behera (India), Dikla Benzeevi (USA), Aseem Rai Bhatnagar (India), Ivana Bozovic (Belgium), Ruta Briediene (Lithuania), Corrado Chiappa (Italy), Alessia Desimone (Italy), Simona Di Lascio (Switzerland), Linda Dias (Canada) - Rowena Enriquez (Malta), Michelle Esser (USA) - Waleed Fayez Ali Fahmy (Ireland), Nahla Gafer (Sudan), Hanan Gewefel (Egypt), Ajay Gogia (India), Elena Gorincioi (Moldova), Monika Jankowska (Poland), Paras Khanna (India), Surender Kumar (India), Prashant Kumbhaj (India), Matteo Lambertini (Italy), Stacy Lewis (USA), Visnu Lohsiriwat (Italy),, Wijden Mahfoudh (Tunisia), Jelena Masksimenko (Latvia), Stella Mastora (Cyprus), Imene Oueslati (Tunisia), Lazar Popovic (Serbia), Shoshana Rosenberg (USA), Abhinav Arun Sonkar (India), Elisa Vicini (Italy), Kaloyan Yordanov (Bulgaria)

Aer Lingus is delighted to assist delegates attending the BCY1 - Breast Cancer in Young Women Conference.
Please go to www.aerlingus.com/conference/bcy/ for more information on group bookings, direct flights, connecting flights, fares and availability.

A valid passport and/or identity card is required for entry into Dublin. A visa may be required for some countries. For specific information, please visit the department of Foreign affairs and Trade website at www.dfa.ie

Free Wi-Fi internet access in all areas of the ABC1 venue will be available.

Please note that capturing contents of the sessions is prohibited.

Wednesday, 7 November  10:00-17:00
Thursday, 8 November  9:00-18:30
Friday, 9 November  8:00-17:30
Saturday, 10 November   8:00-14:00

Thursday, 8 November  13:30-19:00
Friday, 9 November  9:00-18:30
Saturday, 10 November   8:30-13:00

- Abstracts: 15 July 2012
- Travel grants: 15 July 2012
- Early registration: by 5 August 2012
- Late registration: by 14 October 2012
- On-site registration: after 14 October 2012

Invitation to Sponsors can be downloaded here. For further information, please contact Francesca Marangoni (fmarangoni@eso.net)

Faculty list

Fatima Cardoso, Champalimaud Cancer Center, Lisbon, PT
Bella Kaufman, Sheba Medical Center, Tel Hashomer, IL
Anne H. Partridge, Dana-Farber Cancer Institute, Boston, US
J. Geraghty, St Vincent's Hospital, Dublin, IE

S. Aebi
, University Hospital Berne - Inselspital, Berne, CH
H.A. Azim Jr., Jules Bordet Institute, Brussels, BE
G. Freilich, Europa Donna, London, UK
M.C. King, University of Washington - School of Medicine, Seattle, US
F.A. Peccatori, European Institute of Oncology, Milan, IT

O. Abulkhair
, King Abdulaziz Medical City for National Guard, Riyadh, SA
F. Amant, U.Z Gasthuisberg, Leuven, BE
C. Anders, UNC Linenberger Comprehensive Cancer Center, Chapel Hill, US
J. Armstrong, St. Luke's Institute of Cancer Research, Dublin, IE
A.G. Arnold, Memorial Sloan Kettering Hospital, New York, US
F.A. Calvo, Hospital General Universitario Gregorio Marañon, Madrid, ES
E. Cauzza, Ospedale Regionale Bellinzona e Valli, Bellinzona, CH
A.M. Cluxton, Young Survival Coalition, Columbus, US
R.E. Coleman, Weston Park Hospital, Sheffield, UK
M. Colleoni, European Institute of Oncology, Milan, IT
E. Connolly, St. James Hospital, Dublin, IE
A. Costa, European School of Oncology, Milan, IT
J. Crown, NICB Dublin City University, Dublin, IE
S. Delaloge, Institut Gustave Roussy, Villejuif, FR
J. Dix, Adoption Consultant, Isle of Wight, UK
E. Furlong, University College Dublin, Dublin, IE
J. Garber, Dana Farber Cancer Institute, Boston, US
O.D. Gentilini, European Institute of Oncology, Milan, IT
A. Graziottin, Saint Raffaele Resnati Hospital, Milan, IT
A. Green, School of Medicine & Medical Science, Dublin, IE
N. Harbeck, Breast Center, University of Munich, DE
M. Kell, University College Dublin, Dublin, IE
C. Kelly, Mater Misericordiae Hospital, Dublin, IE
J. King, Royal Free Hampstead NHS TrusT, London, UK
C.K. Kuhl, Aachen University Clinic, Aachen, DE
S. Loibl, German Breast Group, Neu-Isenburg, DE
E.W. McDermott, St. Vincent Hospital, Dublin, IE
D. Meirow, Sheba Medical Center, Tel Aviv, IL
E. Mocanu, Rotunda Maternity Hospital, Dublin, IE
A. O'Doherty, National Cancer Screening Service, Dublin, IE
G. O'Dowd, Irish Cancer Society, Dublin, IE
O. Pagani, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
S. Paluch-Shimon, Sheba Medical Center, Tel Hashomer, IL
I. Smith, Royal Marsden Hospital, Sutton Surrey-London, UK
A. Tutt, Kings College London School of Medicine, Guy's Hospital Camp, London, UK


7 November


Registration opens for individual participants and for groups


8 November


Christine Murphy Whyte memorial lecture
Chair: J. Geraghty, IE


Presentation for a Young Irish Patient
G. O’Dowd, IE


Presentation from the Young Survival Coalition
A. Cluxton, US [Abs IN1]


Breast cancer in Young Women: the magnitude of the problem
B. Kaufman, IL


SESSION I: Debate: The biology of breast cancer in young women is unique

 14:25 Introduction by Chair (J. Garber, US)
14:30 In favour (M. Colleoni, IT) [Abs IN2]
14:50 Against (C. Anders, US) [Abs IN3]


Coffee break


SESSION II: Familial and hereditary breast cancer
Chair: A. Green, IE


15:40 Biology of BRCA - associated breast cancer (A. Tutt, UK) [Abs IN4]
16:00 Genetic counselling and testing (A.G. Arnold, US) [Abs IN5]
16:20 Cancer risk-reducing measures for high risk women (J. Garber, US) [Abs IN6]
16:45 The woman’s perspective (G. Freilich, UK) [Abs IN7]


Best Abstracts presentations 
Chairs: E. Connolly, IE and M. Kell, IE
  • Chemotherapy-induced ovarian failure as a prototype for acute             
    vascular toxicity       
    I. Ben-Aharon, IL [Abs OR26]
  • Sexual functioning in young women with breast cancer   
    S. Rosenberg, US [Abs OR34]
  • Young and metastatic: addressing the unique needs of advanced          
    breast cancer in young women 
    S. Lewis, US [Abs OR77]


Case discussion session 1
Moderators: B. Kaufman, IL and S. Paluch-Shimon, IL
Panel: Speakers and Chairs


9 November


SESSION III: Staging of breast cancer in young women
Chair: A. O’Doherty, IE


09:00 How to best use available techniques (C.K. Kuhl, DE)
09:20 Emerging technologies (T. Gagliardi, UK) [Abs IN8]


SESSION IV: Loco-regional therapy. What should be different in young women
Chairs: J. Geraghty, IE and J. Armstrong, IE


09:40 Surgery (O.D. Gentilini, IT) [Abs IN9]
10:00 Radiotherapy (F.A. Calvo, ES) [Abs IN10]


Coffee break


SESSION V: Adjuvant systemic therapy
Chairs: N. Harbeck, DE and A.H. Partridge, US


11:00 Endocrine therapy for early breast cancer: standards and controversies (O. Pagani, CH)         [Abs IN11]
11:25 Debate: All young early breast cancer patients should receive adjuvant chemotherapy        11:25 Introduction by Chair (S. Aebi, CH)        11:30 In favour (F.A. Peccatori, IT) [Abs IN12]        11:50 Against (S. Delaloge, FR) [Abs IN13]
12:10 Adjuvant bisphosphonates for young early breast cancer patients 
         12:10 Bisphosphonates in the adjuvant setting: ready for prime time? (I. Smith, UK) [Abs IN14]        12:35 RANKL signalling: bone metastasis and beyond (R.E. Coleman, UK) [Abs IN15]


Lunch and poster session


SESSION VI: Advanced breast cancer
Chair: S. Aebi, CH
 14:30 Advanced breast cancer in young women: what should be different? (F. Cardoso, PT)
14:55 Advances in targeted therapy (N. Harbeck, DE) [Abs IN16]


Case discussion session II
Moderators: A.H. Partridge, US and O. Abulkhair, SA
Panel: Speakers from and Chairs from sessions V and VI


Coffee break


SESSION VII: Fertility and adoption
Chairs: E.W. McDermott, IE and E. Mocanu, IE

 16:30 Fertility preservation (D. Meirow, IL) [Abs IN17]
16:55 Can I adopt a child? (J. Dix, UK) [Abs IN18]

10 November


SESSION VIII: Quality of life issues 
Chairs: A. Costa, IT and J. King, UK


08:30 Management of early menopause associated symptoms (A.H. Partridge, US) [Abs IN19]
08:55 The young couple and breast cancer (A. Graziottin, IT) [Abs IN20]
09:15 “Mommy has breast cancer”: how do the children cope? (E. Furlong, IE) [Abs IN21]


SESSION IX: Breast cancer and pregnancy
Chairs: F. Cardoso, PT and C. Kelly, IE


09:30 Breast cancer during pregnancy: the oncologist perspective (S. Loibl, DE) [Abs IN22]
09:50 Breast cancer during pregnancy: the obstetrician/paediatric perspective (F. Amant, BE) [Abs IN23]
10:10 Pregnancy after breast cancer (H.A. Azim Jr, BE) [Abs IN24]
10:25 Pregnancy registry and trial project (O. Pagani, CH) [Abs IN25]


Coffee break


Case discussion session III
Moderators: F.A. Peccatori, IT and C. Kelly, IE
Panel: Speakers, Chairs and patient representative


SESSION X: Breast Cancer in Young Women Conference Statement
Chairs: B. Kaufman, IL - A. Partridge, US and F. Cardoso, PT
Panel: S. Aebi, CH - F. Amant, BE - H.A. Azim Jr, BE - F.A. Calvo, ES - S. Delaloge, FR - G. Freilich, UK - T. Gagliardi, UK - J. Garber, US - O.D. Gentilini, IT - N. Harbeck, DE - C.K. Kuhl, DE - S. Loibl, DE - D. Meirow, IL - O. Pagani, CH -
F.A. Peccatori, IT


Closing remarks
J. Geraghty, IE


 Chemotherapy-induced ovarian failure as a prototype for acute vascular toxicity. Irit Ben-Aharon, IL
OR34 Sexual functioning in young women with breast cancer. Shoshana  Rosenberg, US
OR77 Young and metastatic: addressing the unique needs of advanced breast cancer in young women. Stacy Lewis, US
HM35 Role of temporary ovarian suppression obtained with GnRH analogue in reducing premature ovarian failure induced by chemotherapy in premenopausal cancer patients: a meta-analysis of randomized studies. Matteo Lambertini, IT
HM36 Work-life after breast cancer treatment: a European patient survey. Jeremy Braybrooke, UK
PO27 HER2 and steroid receptor status in pregnancy-associated breast cancer. Maria Litwiniuk, PL
PO28 Review of indeterminate (B3) breast core biopsy in young women in one centre in southwest England. Richard Hunt, UK
PO29 The role of nipple smears in young women and their value in cancer diagnoses in one centre in southwest England. Richard Hunt, UK
PO30 Operable breast cancer in very young women, is there a difference?  Jelena Maksimenko, LV
PO31 FASL -844 T/C polymorphism: a biomarker of good prognosis of breast cancer in young patients. Wijden Mahfoudh, TN
PO32 Metabolomic changes in young breast cancer patients by proton high resolution magic angle spinning (hrmas) technique - a pilot study. Abhinav Arun Sonkar, IN
PO37 Outcomes in pregnancy associated breast cancer: a single centre experience. Sreedevi Kumar, UK
PO39 Placental weight and mortality in premenopausal breast cancer by tumor characteristics. Mohammadhossein Hajiebrahimi, SE
PO40 Impact of quality of interstitial brachytherapy in early stage breast cancer in young women. Manoj Behera, IN
PO41 An overview of young breast cancer patients. Ajay Gogia, IN
PO43 Study of two different dose fractionation schedules of post mastectomy chest wall irradiation in carcinoma breast patients. Prashant Kumbhaj, IN
PO44 Impact of recent parity on histopathological tumour features and outcome of premenopausal women with breast cancer. Chikako Shimizu, JP
PO45 Quality of life in younger age group breast cancer patients undergoing oncoplastic breast surgery: a comparative case series analysis. Surender Kumar, IN
PO46 Young women with breast cancer do well following immediate breast reconstruction in a networked  regional-tertiary service . Ryan Sugrue, IE
PO47 Nipple-sparing mastectomy for risk reducing surgery in young women. Visnu Lohsiriwat, IT
PO48 Mental health status after breast cancer treatment: a longitudinal assessment of survivors diagnosed prior to age 40. Michelle Naughton, US
PO49 Young age at breast cancer (BC) diagnosis in the Middle East: impact on prognosis and pattern of relapse. Omar Abdelrhman, EG
PO50 Prognostic value of young age, carcinoma receptor subtypes and pathologic tumour characteristics on survival of Caucasian women with breast cancer. Solomon Lee, US
PO51 Carcinoma of the breast in the young Egyptian females. Ahmed Tarek Awad, EG
PO53 The accuracy of combined  mammography and breast ultrasound over ultrasound alone  in young women below 40 years. Hanan Gewefel, EG
PO54 Influence of unconventional therapies on the outcome of breast cancer in young north Indian women: a multicentre study. Farah Arshad, IN
PO55 Breast conservation in the young (< 40 year) triple negative breast cancer patient. Paras Khanna, IN
PO56 Prevalence of early menopause/secondary amenorrhea in premenopausal women diagnosed with early breast cancer who received adjuvant or neoadjuvant treatment based on docetaxel. Daniel Lopez-Trabada Ataz, ES
PO57 The burden of breast cancer in young women in Lagos University Teaching Hospital (LUTH). Adedapo Osinowo, NG
PO58 Early onset breast cancer: clinical characteristics and patterns of relapse in BRCA1/2 mutation carriers compared to non-carriers. Georgeta Fried, IL
PO59 Breast conserving surgery and whole breast radiation therapy followed by high dose rate brachytherapy boost versus electron beam boost in the treatment of early breast cancer in young Indian women: which is cosmetically better? Aseem Rai Bhatnagar, IN
PO60 Characterization of a young women population affected with breast cancer and tested for brca1/brca2 gene mutations: a monocentric series. Monica Zuradelli, IT
PO61 Breast cancer in young women: a single institution experience . João Pedro Neves, PT
PO63 A new minimally invasive technique for risk reduction surgery in high risk women. Alberta Ferrari, IT
PO64 Clinical characteristics and trends in treatment of breast cancer among young women: a national population-based study. Marianna de Camargo Cancela, IE
PO66 Triple negative breast cancer in young patients in India. Anupama  Mane, IN
PO67 The outcome of patients with pregnancy associated breast cancer: retrospective review. Shaista Khan, PK
PO68 Breast cancer in young patients in the Galilee. Amram Hadary, IL
PO69 The rate of mastectomies and breast  conservative surgery in  young women with breast cancer in Albania. Elvisa Kozma, AL
PO70 Breast cancer in young women - scenario of sub optimal surgery from a developing world. Akshay Anand Agarwal, IN
PO78 Symptomatic breast service: quality improvements in the triage process of tertiary referrals. Grainne Sheeran, IE
PO79 A novel strategy to equip health care providers serving young breast cancer patients. Michelle Esser, US
PO80 Addressing the unique psychosocial needs of young women with breast cancer post-treatment. Stacy Lewis, US
PO81 Considering the young, long-term breast cancer survivor: identifying needs of young women five or more years post-treatment. Michelle Esser, US
PO82 Sexual functioning in young women after breast cancer treatment. Monika Jankowska, PL
PO83 Beyond statistics: how analysing blog narratives enhances nursing's understanding of the survivorship experience of younger women with breast cancer. Marie Ennis, IE
PO85 Do young women with breast cancer have another expectations of psychological support than the others? Radoslaw Tarkowski, PL
PO86 Qualitative study of challenges facing young women following mastectomy for breast cancer: a preliminary study. AbdulRazzaq Lawal, NG

No responsibility is assumed by the organisers for any injury and/or damage to persons or propriety as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Organisers recommend that independent verification of diagnosis, therapies and dosages should be made. Every effort has been made to faithfully reproduce the materials as submitted. However, no responsibility is assumed by the organisers for any omissions or misprints.

Irit Ben-Aharon, Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach-Tikva, IL
Stacy Lewis, Young Survival Coalition, New York, US
Shoshana  Rosenberg, Harvard School of Public Health, Boston, US




Abstracts will be assessed for oral and poster presentation at the conference, or for publication only in the BCY1 Abstract Book which will be published as a supplement of The Breast.

• The three best abstracts will be selected for a 5-minute oral presentation on Thursday, 8 November and for poster presentation on Friday, 9 November. Free registration will be granted to the first author of the three selected
• Further abstracts will be selected for poster presentation on Friday, 9 November.

Participants are invited to submit an abstract on breast cancer in young women, in one of the following categories:

• Basic/Translational Research;
• Clinical Research;
• Advocacy and Nursing 

• The abstract should be limited to 2000 characters, including the title
• The title should be in lower case letters
• Each author should be listed with First Name, followed by Family Name
• The first author should be underlined (first author = corresponding author and presenter)
• List affiliations after the authors’ list
• The full address with e-mail address, phone and fax numbers of the first author (+ corresponding author and presenter) must be provided. The first author will receive an acknowledgement of receipt and all subsequent  
communication by e-mail.
• For abstracts accepted for presentation, the first author will be the presenting author and is requested to register and participate in the Conference.
• It is the responsibility of the first author to ascertain whether all authors are aware of the content of the abstract before submission is made.

The acknowledgement of receipt of the abstract will immediately follow the submission. The outcome will be notified by 20 July to the first author who will be required to register to the Conference (early registration deadline: 5 August).